Strengthening immunisation systems and introduction of hepatitis B vaccine in Central and Eastern Europe and the Newly Independent States

Kyiv, Ukraine, 25-28 May 2004

Overall Goal:
Contribute towards a sustainable progress of public health in the CEE and NIS region by sharing experiences and knowledge that will help to reinforce the current vaccination programmes and facilitate the introduction of future vaccines.

Objectives of the meeting:

  • Provide participants with an overview of the current epidemiological situation of viral hepatitis infection worldwide and in the European Region of the World Health Organization (WHO)
  • Provide participants with an overview of the Global Alliance for Vaccines and Immunization (GAVI), the Vaccine Fund (VF) and related activities in the WHO European Region
  • Provide an overview of the current status of hepatitis B vaccination globally and in the WHO European Region
  • Discuss financial sustainability issues of hepatitis B vaccination in GAVI and non-GAVI countries and share country experience
  • Discuss status and options of vaccine procurement for non-GAVI countries in Central and Eastern Europe and the NIS 
  • Review safety of vaccines, including hepatitis B vaccines, and vaccination and how to communicate on these topics
  • Discuss transition issues with the availability of monovalent and combined vaccines
  • Discuss the roles of various partner agencies and organisations in vaccination programmes

Tuesday, May 25th 2004

SESSION 1: OPENING SESSION

18.00-19.00 Welcome by:

Nedret Emiroglu, WHO
Olga Lapushenko, Ministry of Health, Ukraine
Dragoslav Popovic, UNICEF
Mark Kane, Children’s Vaccine Program

Review of the objectives of the meeting and technical introduction

Wednesday, May 26th 2004

08.30-09.00  REGISTRATION (continued)

SESSION 2: GENERAL INTRODUCTION

09.00 - 09.20 Global Epidemiology and prevention of hepatitis B
Steven Wiersma, WHO

09.20 - 09.40  Overview of GAVI and the Vaccine Fund
Tore Godal, GAVI

09.40 - 10.00 GAVI in the WHO European Region: results, current situation, and future
Andrei Lobanov, WHO

SESSION 3: EPIDEMIOLOGY AND PREVENTION OF VIRAL HEPATITIS   AND   HEAMOPHILUS INFLUENZAE TYPE B

10.30 - 10.50 Epidemiology of hepatitis B and vaccination programmes in the WHO European Region
Nedret Emiroglu, WHO

10.50 - 11.00 Discussion

11.00 - 11.20 Hepatitis C epidemiology in CEE and NIS countries
Hal Margolis, CDC

11.20 - 11.30 Discussion

11.30 - 11.50 HBV, HCV, and HIV integrated programmes
Michael Favorov, CDC

11.50 - 12.00 Discussion

14.00 - 14.20 Burden of disease of Haemophilus influenzae type b in the WHO European Region
Andrei Lobanov, WHO

14.20 - 14.30 Discussion

SESSION 4: COUNTRY EXPERIENCES: HEPATITIS B PREVENTION STRATEGIES AND PROGRAMME EVALUATION[15 minutes presentation and 5 minutes discussion time for each topic]
 
14.30 - 14.50 Introduction of a newborn hepatitis B immunisation programme in Turkey
Ebru Usta and Selim Badur, Turkey

14.50 - 15.10 Achievements with newborn and catch up hepatitis B immunisation programme in Kazakhstan
Tatiana Surdina, Kazakhstan

15.10 - 15.30 Assessment of implementation of the hepatitis B prevention programme in Georgia
 Lia Dzhabidze, Georgia

16.00 - 16.20 Evaluation of hepatitis B prevention strategies in the Russian Federation
Marina Shevyreva, Russian Federation

16.20 - 16.40 Experience with sentinel surveillance in Kyrgyzstan
Rafik Usmanov, Kyrgyzstan

16.40 - 17.00 Acute Viral Hepatitis Surveillance for Hepatitis B Vaccine Evaluation Program
Liudmila Mosina, CDC

Thursday, May 27th 2004

SESSION 5:  SAFETY ISSUES
 
09.00 - 09.20 Safety and quality of hepatitis B vaccines: Frequently asked questions in the WHO European Region
Philippe Duclos, WHO

09.20 - 09.40 The importance of communication on immunisation safety
Dragoslav Popovic, UNICEF

09.40 - 10.00 Injection safety of immunisation in the WHO European Region
Denis Maire, WHO

10.00 - 10.15 Blood safety in Central Asia Region
Aliya Jumagulova, CDC

10.15 - 10.30 Safe sharps waste collection and management in Samarkand, Uzbekistan
Erkin Musabaev, Uzbekistan

10.30 - 11.00 Discussions  

SESSION 6: STRENGTHENING IMMUNISATION SYSTEMS: PROCUREMENT AND FINANCING

11.30 - 11.50 Vaccine supply in CEE and NIS
Katinka Aanjesen, UNICEF

11.50 - 12.10 Potential role of group procurement in the WHO European Region
Alan Brooks, CVP/PATH

12.10 - 12.30 Discussions

14.00 - 14.20 Financial sustainability planning
Viktor Galyada, CVP/PATH

14.20 - 14.35 Financial sustainability planning of Uzbekistan
Dilorom Tursunova, Uzbekistan

14.35 - 14.50 e-learning resource to strengthen financial planning of immunization
Molly Mort and Alan Brooks, CVP/PATH
  
14.50 - 15.10 Discussions

SESSION 7A: TECHNICAL WORKSHOP: HOW TO MONITOR AND EVALUATE HEPATITIS B IMMUNISATION PROGRAMMES  AND  TO SET SURVEILLANCE TARGETS

Chairs: Susan Goldstein, CDC;  Johannes Hallauer, VHPB

15.30 - 15.55 Overview of methods to evaluate the impact hepatitis B immunization programs
Susan Goldstein, CDC

15.55 - 16.20 Practical aspects of conducting acute disease surveillance
Rafik Usmanov, Kyrgyzstan

16.20 - 16.45 Laboratory aspects of acute disease surveillance and the need for QA/QC
Tatiana Kalashnikova, CDC

16.45 - 17.10 Protocol to conduct serologic surveys
Luidmila Mosina, CDC

17.10 - 17.35 WHO protocol for serologic surveillance
Steven Wiersma, WHO

17.35 - 18.00 Open Discussion

SESSION 7B: TECHNICAL WORKSHOP: HEPATITIS B VACCINES
Chairs: Wolfgang Jilg, VHPB; Paolo Bonanni,VHPB; Pierre Van Damme, VHPB

15.30 - 15.40 Introduction

15.40 - 16.00 Birth dose: what is possible in view of other vaccines, combined vaccines, etc
Reflections on schedules, dosage, vaccines and inter-changeability of hepatitis B vaccines

Mark Kane,CVP/PATH or Pierre Van Damme, VHPB

16.00 - 16.30 Duration of protection after hepatitis B vaccination: current status
Wolfgang Jilg, VHPB
 
16.30  - 16.45 Current experience in Italy
Paolo Bonanni, VHPB

16.45 - 17.00 Review of current  recommendations regarding booster vaccination
Daniel Lavanchy, WHO

17.00 - 17.30 Country experience on current vaccination policy: booster, schedules, vaccine, doses, etc.:
Workshop discussion with country participants

17.30 - 17.50 Pre- and post-vaccination testing and the issue of non-responders
Fransisco Averhoff, CDC

17.50 - 18.00 Final open questions and answers to facilitators/ conclusions

SESSION 7C: TECHNICAL WORKSHOP: HOW TO MANAGE A VACCINE SAFETY CRISIS IN YOUR COUNTRY: WHAT TO DO, WHAT TO AVOID? (ADVOCACY, SOCIAL MOBILIZATION)
Chairs: Dragoslav Popovic, UNICEF; Philippe Duclos, WHO

15.30 - 15.45 Introduction of participants, objectives of the workshop, agenda

15.45 - 15.55 Why and how to deal with media?

15.55 - 16.35 Press Conference: Role play

16.35 - 17.20 Case studies: Response to safety crisis and development of a checklist on “crisis management”
Group Work

17.20 - 17.40 Rapport from the working groups/discussion

17.40 - 18.00 How to access major sources in communication for immunization
Discussion

SESSION 7D: GAVI WORKSHOP: FINANCIAL SUSTAINABILITY PLANS (FSP)
Chairs: Andrei Lobanov,WHO; Viktor Galyada,CVP/PATH; Alan Brooks, CVP/PATH

15.30 - 15.45 Introduction

15.45 - 16.25 Countries briefly describe the development process

16.25 - 16.40 Implementation of FSP in Kyrgyzstan
Ludmila Shteinke, Kyrgyztan

16.40 - 17.15 Countries describe what is being done to maintain rolling financial planning for immunization, including implement strategies in the FSP

17.15 - 17.45 Getting the 2004 process started

17.45 - 18.00 Final open questions and answers to facilitators or other countries

Friday, May 28th 2004

SESSION  8:  FEEDBACK  OF THE  WORKSHOPS

09.00 - 09.15 Feedback on workshop 7A: How to monitoring and evaluate hepatitis B immunisation programmes and set surveillance targets

09.15 - 09.25 Discussion

09.25 - 09.40 Feedback on workshop 7B: Technical aspects of hepatitis B vaccines

09.40 - 09.50 Discussion

09.50 - 10.05 Feedback on workshop 7C: How to manage a vaccine safety crisis in your country

10.05 - 10.15 Discussion

10.15 - 10.30 Feedback on workshop 7D: Financial sustainability plans

10.30 - 10.40 Discussion

SESSION 9:  CONCLUSIONS OF THE MEETING AND CLOSING REMARKS

11.10 - 12.00 Conclusions and summary of the meeting
Alexandra Levitt

BREAK-OUT SESSION FOR COUNTRIES RECEIVING SUPPORT FROM GAVI / VACCINE FUND

14.00 - 17.00  A programme of the session will be provided

Tags: